Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Study identifies potential new bone disease target

Feb. 28, 2022

STING signaling in beta cells maintains glucose homeostasis

Feb. 28, 2022

New free fatty acid receptor 1 agonists identified at Rezubio Pharmaceuticals

Feb. 28, 2022

Jnana selects JNT-517 as development candidate for phenylketonuria

Feb. 24, 2022

MZE-001 shows promising results in murine and canine models of Pompe disease

Feb. 23, 2022

Blockade of HIF-1 leads to ROS overproduction in diabetes

Feb. 23, 2022

Researchers present in vitro data for GYS1 inhibitor MZE-001 in Pompe disease

Feb. 22, 2022

RosVivo signs material transfer agreement with Lilly for RSVI-301 for diabetes

Feb. 22, 2022

Pharmacological IRE1/XBP1s activation mitigates obesity-driven metabolic dysfunction

Feb. 17, 2022

Novo Nordisk discovers GIP-R/GLP-1 receptor coagonists

Feb. 17, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.